42 results about "Ovarian cell" patented technology

Disclosed are methods for diagnosing ovarian cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic ovarian cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.

The invention provides an ovarian cell microcapsule, which adopts alginate-poly-lysine- alginate (APA) to encapsulate ovarian cells and prepare a microcapsule containing ovarian cells inside. The ovarian cells in the microcapsule consists of ovarian granulosa cells and theca cells, which has endocrine function; undifferentiated ovary inner mesenchymal cells and connective tissue cells. If allogenously plant the microcapsule of the invention, the endocrine cells in the microcapsule can constantly secret sex hormone in body, and the endocrine function can be under the control of neuroendorine of the body to reach the aim of personalized supplementing the inefficiency of sex hormone endocrine. The allogenous plant of ovarian cell microcapsule has positive prevention and treatment effects to body degenerative lesion. Experiment shows that the invention can alleviate the loss of bone quantity and presents positive effect to the prevention and treatment of osteoporosis; meanwhile, the invention can affect the biological activity of islet Alpha cell and Beta cell, and regulate the endocrine of insulin and glucagons.

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as EOC cells if the expression of Sox11 is up-regulated compared to normal B-cells. Preferably EOC cells are identified as improved recurrence-free survival-associated if expression of Sox11 is up-regulated compared with non-cancerous epithelial ovarian cells. Preferably, EOC cells are identified as diminished recurrence-free survival-associated if expression of Sox11 is similar to, or down-regulated, compared with non-cancerous epithelial ovarian cells.

The invention provides the application of iridoid compound to the preparation of ovarian cancer resistance medicament. The iridoid compound is isovaleric acid base dihydro valerian element or isovaleric acid base dihydro valepotriate J which has the following structural formula. The experiments on the toxic and killing effect of the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J on the p 53 wild ovarian cancer cells A2780, the p53 mutated OVCAR-3 cells and the normal ovarian cells IOSE144 show that the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J has the selective toxic and killing effect on the ovarian cancer cells and can inhibit the proliferation of ovarian cancer cells and kill the ovarian cancer cells. The iridoid compound can be used as the active component to prepare the ovarian cancer resistance medicament. The invention provides the novel ovarian cancer treatment medicament for the clinical treatment of the ovarian cancer and brings the joyous news to the patients with the ovarian cancer. The iridoid compound has higher application value.

The invention relates to methods for producing recombinant human zona pellucida protein ("rhZP3") and glycosylated peptide having biological activity of binding to human spermatozoa. A human ovarian cell line is used to produce rhZP3 having a glycosylation pattern required for full biological activity. Methods of determining useful peptides with binding activity for human sperm and their syntheses, as well as using such peptides and proteins in therapeutics and diagnostics are discussed.

A method for isolating oogonial stem cells (OSCs) including forming an ovarian cell suspension from an ovary, forming ovaroids by culturing the ovarian cell suspension in a three-dimensional culture, and migrating the OSCs around the ovaroids by culturing the ovaroids on a mouse embryonic fibroblast (MEF)-coated plate.

The present invention provides glycoprotein hormone analogs having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide. The analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond. The present invention also provides a method for stimulating fertility in mammals by promoting apoptosis of ovarian cells and/or luteal cells, which comprises administering to the mammal a therapeutically effective amount of a glycoprotein hormone analog having partial agonist/antagonist activity.

The invention discloses a method for expressing pramlintide, and belongs to the technical field of genetic engineering. The method is characterized by comprising the following steps: conducting bacterial infection on bombyx mori ovary cells by virtue of a baculovirus multi-gene expression system, so that a baculovirus, which is capable of simultaneously expressing a human-derived amidating enzyme and the pramlintide; and then, injecting the virus into five-instar bombyx mori bodies, so that the amidating enzyme and the pramlintide are co-expressed by the bombyx mori, wherein glycine at the C terminal of the pramlintide is directly amidated by the amidating enzyme, so that the pramlintide, having an activity, is produced, and the pramlintide is purified by virtue of conventional purification means. With the application of the method disclosed by the invention, a plurality of genes can be expressed, which is conducive to co-expression of the human-derived amidating enzyme and the pramlintide; the method disclosed by the invention, which makes use of the bombyx mori bioreactor, is high in protein expression amount and is more complete in modification; and the method disclosed by the invention is short in production time, high in efficiency and low in production cost.

The invention belongs to the technical field of biomarkers, and relates to an application of a biomarker to preparation of a reagent/reagent group for diagnosing ovarian cell apoptosis and injury caused by heavy metal uranium. The biomarker is selected from one, more or all of the following genes: Casp3, Fos, Tgfb2, Fgf17, Faslg, Dusp2, Fgf9, Cacng5, Relb, Gadd45b, Hspa1a, Fgf7, Rap1a, Pla2g4c, Cacna1i, Cacna1b, Myc, Pla2g4f, Hspb1, Jun, Cacna1c, Ddit3, Dusp8, Cacnb4, Cacna1f, Rasgrp2, Map4k2, Nr4a1, Rac3, Fgfr4, Map4k1, Cacna1d, Fgf8, Mapk11 and Cd14. By utilizing the application of the biomarker to preparation of the reagent/reagent group for diagnosing ovarian cell apoptosis and injury caused by heavy metal uranium, the biomarker for diagnosing ovarian cell apoptosis and injury caused by heavy metal uranium can be screened out, and analysis of biological functions and pathways influenced by the biomarkers is performed.

The invention provides a mythimna separata pupa ovary cell line capable of highly yielding baculovirus. The cell line is named as IOZCAS-Myse-1 and assigned the accession number CGMCC No.17282. A construction method of the cell line is provided. The method includes the following steps: step 1) obtaining mythimna separata ovary tissue; step 2) culturing the mythimna separata ovary tissue until a culture flask is filled with proliferative cells, wherein the tissue is closely attached to the bottom of the cell culture flask; and step 3) taking newly proliferative single cells, performing continuous culture until cell passage so as to obtain the cell line. The whole process is conducted under an aseptic condition. The provided cell line can be used for copying baculovirus, so that the baculovirus or baculovirus insecticide can be produced in large scale; and the cell line can also be applied to express the protein having commercial or scientific values by using a constructed baculovirus expression vector system.

The invention provides a superovulation polyvinylpyrrolidone FSH composite slow-release injection for sika deer. Four substances, such as FSH, acidic xylosidase, cellulase and gentamicin, are uniformly dispersed in polyvinylpyrrolidone so as to form a slow release agent; and according to a synergistic effect of medicines such as FSH, acidic xylosidase, cellulose, gentamicin and the like, target substances and indirectly produced nutrient substances can continuously and uniformly act on ovary cells so as to promote follicle growth and maturity; and therefore, a good effect on superovulation is achieved, and the mature ovum is high in quality. According to the dosage form, stress reaction is reduced by intravenous injection, and intense struggling caused by pain is alleviated.

The invention relates to the technical field of medicines, in particular to injection for treating premature ovarian failure. The injection comprises 50 to 200 milligrams of flavone, 10 to 30 milligrams of Vitb6, 1.8 to 3.2 grams of glutathione, and 3 to 8 grams of Vit c. The injection enters human body by injecting, is directly absorbed, can effectively and lastingly activate the functions of ovarian cells, repair special nutritional substances of atrophic ovary, promote female hormone balance, improve climacteric symptoms and particularly improve secretion of female hormone and progestogen, and has a remarkable curative effect; the injection is used for comprehensively conditioning various symptoms caused by female endocrine dyscrasia, and has remarkable effects of improving the immunity of the body, preventing osteoporosis and quickly eliminating the symptoms such as hot flash, hidrosis, insomnia, dysphoria, waist soreness, backache, menstrual disorder, skin stain and lumbar and abdominal obesity; and the injection avoids risks and potential safety hazards caused by estradiol in conventional therapy.

The invention discloses a medicine composition for inhibiting ovarian carcinoma cells, and belongs to the technical field of the biological medicine. The composition is formed by combining 200ng/mL ofbrefeldin A (BFA) and 4.0-5.0microgram/mL of cisplatin (CDDP). The medicine composition can obviously inhibit the growth proliferation of the ovarian carcinoma cells and accelerate the apoptosis of the ovarian carcinoma cells, has a function of adjusting genes and protein related to the apoptosis of the ovarian carcinoma cells, is obvious superior to the individual medication, and has the effectof synergistically resisting the ovarian carcinoma cells. The medicine composition can be used as a target medicine composition for regulating and controlling the apoptosis pathway of the ovarian carcinoma cells, thereby providing a new comprehensive treatment strategy for the ovarian carcinoma clinically.

The invention discloses a preparation method of menstrual blood mesenchymal stem cells, the cell source is novel adult stem cells separated and cultured from female menstrual blood, the cell source is rich, the separation and culture process is safe and simple, the menstrual blood mesenchymal stem cells can be massively researched and used, the stem cells separated and cultured from female menstrual blood have all the characteristics of mesenchymal stem cells and are extremely easy to proliferate, meanwhile, the menstrual blood mesenchymal stem cells can be induced to be differentiated into various tissue cells including nerve cells, adipose cells, islet cells, ovarian cells and the like and can also be induced into multifunctional stem cells, the research value is high, the menstrual blood mesenchymal stem cells are high in self-renewal capacity, easy to obtain and stable in in-vitro culture, autotransplantation can reduce mental and psychological pressure of patients, the clinical application prospect of the menstrual blood mesenchymal stem cells is far better than that of bone marrow mesenchymal stem cells, chromosome karyotype has no abnormal change after multiple passages, and the safety of the menstrual blood stem cells in the clinical application field is indicated.

The invention provides a separation and purification method of a Leopard Coral Grouper oogonium and identification and application thereof. By adopting the separation and purification method, the oogonium with the proportion of 85.6-90.3% can be obtained from an ovary cell suspension with the oogonium proportion of about 10% through separation and purification; the method has small damage to the cell, the obtained cell is high in activity, the operation process is simple and convenient, used instruments are common, and the method is easy to popularize and use; according to the identification method of the Leopard Coral Grouper oogonium, a hybridization display technology is adopted, a Nanos2 probe is used for marking the oogonium, and the Leopard Coral Grouper oogonium can be quickly identified; the separation and purification method of the Leopard Coral Grouper oogonium provides a technical guarantee for Leopard Coral Grouper reproductive development research and later amplification of a Leopard Coral Grouper male individual by applying an oogonial stem cells with the help of a germ cell transplantation technology.

The invention discloses an ovarian extracellular matrix scaffold and hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biomedicine and clinical medicine. The preparation method of the ovarian extracellular matrix scaffold comprises the following steps: 1) ovarian tissue pretreatment; 2) multi-decellularization treatment: sequentially putting the ovarian tissue skin and marrow treated in the step 1) into double distilled water, a mixed solution of sodium deoxycholate and triton X-100 and a lauryl sodium sulfate solution, sufficiently shaking and washing, adding DNA enzyme, and culturing in a culture medium at 37 DEG C for 4-8 hours; (3) sterilization and freeze-drying treatment: (4) preparation of the ovarian extracellular matrix scaffold: grinding the freeze-drying tissue prepared in the step (3) into particles with the particle size of less than 1mm, and adding acid liquor, pepsase, alkali liquor and a buffer solution into the particles to prepare the ovarian extracellular matrix scaffold. and continuously adding granular cells and follicles into the ovarian extracellular matrix scaffold to prepare the hydrogel material which can be implanted into a mammal body and has the effects of repairing ovarian injury and reconstructing ovarian functions. The research provides a new strategy for female fertility protection.

The invention relates to the technical field of ovarian repair and discloses an ovary egg cell repairing composition and a preparation method thereof. The invention aims to solve technical problems that an existing ovary aging treatment method has a large side effect and an unclear curative effect. The invention provides an ovary egg cell repairing composition. The composition comprises a motherwort herb extract, a kudzuvine root extract, a rhizoma belamcandae extract, a peony root extract, a seaweed extract, a yeast extract, an apple fruit cell culture extract, a golden chamomile extract, a hamamelis virginiana extract, royal jelly freeze-dried powder, collagen, soy isoflavone, xanthan gum, carbomer, disodium glycyrrhizinate, chitosan and a coenzyme A. The invention further provides a preparation method of the ovary egg cell repairing composition. The composition can promote female hormone balance, regulate female reproductive system, promote pelvic blood circulation, enhance ovary immunity, enable ovary to secrete healthy ova, and achieve a purpose of effectively repairing egg cells in ovary.